Submit a Request

Topic: Data & Statistics

Identifying, Addressing, and Treating The Dual Epidemics of Hepatitis C Virus and Opioid Use Disorder

Substance use disorders are common in the United States, with 2024 data indicating that more than 1 in 4 (25.5%) of persons 12 years of age or older used an illicit drug in the past year. The availability of highly effective direct-acting antiviral (DAA) medications has radically changed the assessment and consideration of substance use, and more specifically opioid use, in hepatitis C virus (HCV) treatment decisions. This 90-minute webinar will provide an overview of the hepatitis C virus (HCV), including a focus on defining key epidemiological aspects, contrasting recent treatment advancements, and evaluating the integration of HCV testing and treatment into medications for addiction treatment (MAT)/medications for opioid use disorder (MOUD) programs and opioid treatment programs (OTPs). Attendees will learn practical strategies to improve HCV management and enhance patient outcomes.

Understanding Synthetics: K2, Spice, and the Emergence of Novel Cannabinoids

This one-hour workshop will provide an overview of new and emerging synthetic cannabinoids and their impacts. The session will incorporate identifying different types of cannabinoids, indicators of use, and trends within Nevada and across the country. Participants will learn practical strategies and resources for managing unknown and novel synthetic substance use while understanding up-to-date information that will equip providers to implement effective approaches to engagement and care.  

Southern Nevada Opioid Advisory Council (SNOAC)

The mission of the Southern Nevada Opioid Advisory Council (SNOAC) is to develop a systems-level response to the Southern Nevada substance use crisis through evidence-based strategies and unique community collaborations.

Tobacco Use and Smoking Cessation Among People with Substance Use Disorders: A Summary of the State of the Science and New Evidence from Nevada

Over 80% of people with substance use disorders (SUDs), including opioid use disorder (OUD), smoke cigarettes. While smoking prevalence has decreased in the general population, it remains stubbornly high among people with opioid use disorder (OUD) and other substance use disorders (SUDs). Evidence suggests that conventional smoking cessation treatments are not as successful for people with SUDs as they are in the general population. This training will present the most recent epidemiology on smoking and use of cessation aids among people with SUDs, summarize the state of the science concerning smoking cessation treatment in this population, and present new data from Nevada on a smoking harm minimization intervention using e-cigarettes.